Novo Nordisk
Update in progressNVO (NYSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Novo Nordisk A/S develops, manufactures, and distributes pharmaceutical products through two segments: Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes Care segment provides diabetes, obesity, cardiovascular, and other therapies; Rare Disease covers rare blood and endocrine disorders and hormone replacement. It also offers smart insulin pens (NovoPen 6, NovoPen Echo Plus), Dose Check, growth hormone pens, and injection needles. Headquartered in Bagsværd, Denmark, and active worldwide.
Company score
- Sentiment
- 0.10
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.41
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.41
- Governance
- -0.78
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.10
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE (NYQ)
- LocationDenmark
- CEOMr. Maziar Mike Doustdar B.A.
- Founded1923
- Employees66,700
- Websitewww.novonordisk.com
Identifiers
- ISINUS6701002056
- FIGIBBG000BQBKR3
- LEI549300DAQ1CVT6CXN342
- CUSIP670100205
- CIK0000353278